These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 31622608)

  • 1. Hypoxia inducible factors in the tumor microenvironment as therapeutic targets of cancer stem cells.
    Hajizadeh F; Okoye I; Esmaily M; Ghasemi Chaleshtari M; Masjedi A; Azizi G; Irandoust M; Ghalamfarsa G; Jadidi-Niaragh F
    Life Sci; 2019 Nov; 237():116952. PubMed ID: 31622608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer stem cells (CSCs) in cancer progression and therapy.
    Najafi M; Farhood B; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8381-8395. PubMed ID: 30417375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-mediated cancer stem cell resistance and targeted therapy.
    Sun X; Lv X; Yan Y; Zhao Y; Ma R; He M; Wei M
    Biomed Pharmacother; 2020 Oct; 130():110623. PubMed ID: 32791395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The inhibitory effect of hypoxic cytotoxin on the expansion of cancer stem cells in ovarian cancer.
    Nozawa-Suzuki N; Nagasawa H; Ohnishi K; Morishige K
    Biochem Biophys Res Commun; 2015 Feb; 457(4):706-11. PubMed ID: 25619133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance and cancer stem cells: the shared but distinct roles of hypoxia-inducible factors HIF1α and HIF2α.
    Schöning JP; Monteiro M; Gu W
    Clin Exp Pharmacol Physiol; 2017 Feb; 44(2):153-161. PubMed ID: 27809360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stem cell programs in cancer initiation, progression, and therapy resistance.
    Huang T; Song X; Xu D; Tiek D; Goenka A; Wu B; Sastry N; Hu B; Cheng SY
    Theranostics; 2020; 10(19):8721-8743. PubMed ID: 32754274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
    Rohwer N; Cramer T
    Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness.
    Bao B; Azmi AS; Ali S; Ahmad A; Li Y; Banerjee S; Kong D; Sarkar FH
    Biochim Biophys Acta; 2012 Dec; 1826(2):272-96. PubMed ID: 22579961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer Stem Cells: Basic Concepts and Therapeutic Implications.
    Nassar D; Blanpain C
    Annu Rev Pathol; 2016 May; 11():47-76. PubMed ID: 27193450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells.
    Mimeault M; Batra SK
    J Cell Mol Med; 2013 Jan; 17(1):30-54. PubMed ID: 23301832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models.
    Brooks DL; Schwab LP; Krutilina R; Parke DN; Sethuraman A; Hoogewijs D; Schörg A; Gotwald L; Fan M; Wenger RH; Seagroves TN
    Mol Cancer; 2016 Mar; 15():26. PubMed ID: 27001172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of the breast cancer stem cell phenotype by hypoxia-inducible factors.
    Semenza GL
    Clin Sci (Lond); 2015 Dec; 129(12):1037-45. PubMed ID: 26405042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).
    Kharkar PS
    Expert Opin Ther Pat; 2017 Jul; 27(7):753-761. PubMed ID: 28460551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance.
    Najafi M; Farhood B; Mortezaee K; Kharazinejad E; Majidpoor J; Ahadi R
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):19-31. PubMed ID: 31734836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer stem cell (CSC) resistance drivers.
    Najafi M; Mortezaee K; Majidpoor J
    Life Sci; 2019 Oct; 234():116781. PubMed ID: 31430455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the cancer stem cell phenotype: A step forward in the therapeutic management of cancer.
    Wong ALA; Bellot GL; Hirpara JL; Pervaiz S
    Biochem Pharmacol; 2019 Apr; 162():79-88. PubMed ID: 30689981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
    Yan Y; Zuo X; Wei D
    Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche.
    Lock FE; McDonald PC; Lou Y; Serrano I; Chafe SC; Ostlund C; Aparicio S; Winum JY; Supuran CT; Dedhar S
    Oncogene; 2013 Oct; 32(44):5210-9. PubMed ID: 23208505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways.
    Yan Y; Liu F; Han L; Zhao L; Chen J; Olopade OI; He M; Wei M
    J Exp Clin Cancer Res; 2018 Oct; 37(1):256. PubMed ID: 30340507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update.
    Clara JA; Monge C; Yang Y; Takebe N
    Nat Rev Clin Oncol; 2020 Apr; 17(4):204-232. PubMed ID: 31792354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.